费城染色体阳性急性淋巴细胞性白血病,引领治疗模式的转变

[1]	Moorman AV,Harrison CJ,Buck GA,et al.Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL):analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG)2993 trial[J].Blood,2007,109:3189-3197.
[2]	Pullarkat V,Slovak ML,Kopecky KJ,et al.Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia:results of Southwest Oncology Group 9400 study[J].Blood,2008,111:2563-2572.
[3]	Fielding AK,Rowe JM,Buck G,et al.UKALLXII/ECOG2993:addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia[J].Blood,2014,123:843-850.
[4]	Foà R,Vitale A,Vignetti M,et al.Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia[J].Blood,2011,118:6521-6528.
[5]	Ottmann OG,Pfeifer H,Cayuela JM,et al.Nilotinib (Tasigna) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia chromosome/BCR/ABL1 positive acute lymphoblastic leukemia (ALL):a trial of the European Working Group for Adult ALL (EWALL-PH-02)[J].Blood,2014,123:Abstract 798.
[6]	Jabbour E,Kantarjian H,Ravandi F,et al.Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia:a single-centre,phase 2 study[J].Lancet Oncol,2015,16:1547-1555.
[7]	Vignetti M,Fazi P,Cimino G,et al.Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia with-out additional chemotherapy:results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol[J].Blood,2007,109:3676-3678.
[8]	Ribera JM,García O,Montesinos P,et al.Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation[J].Br J Haematol,2012,159:78-81.
[9]	Chalandon Y,Thomas X,Hayette S,et al.Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia[J].Blood,2015,125:3711-3719.
[10]	Hu Y,Liu Y,Pelletier S,et al.Requirement of Src kinases Lyn,Hck and Fgr for BCR-ABL1 induced B-lymphoblastic leukemia but not chronic myeloid leukemia[J].Nat Genet,2004,36:453-461.
[11]	Ravandi F,Jorgensen JL,Thomas DA,et al.Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy[J].Blood,2013,122:1214-1221.
[12]	Kim DY,Joo YD,Lee JH,et al.Nilotinib combined with multi-agent chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia:interim results of Korean Adult ALL Working Party Phase 2 Study[J].Blood,2011,118:Abstract 1517.
[13]	Fielding AK,Rowe JM,Richards SM,et al.Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era:results from the International ALL Trial MRC UKALLXII/ECOG2993[J].Blood,2009,113:4489-4496.
[14]	Lee S,Kim DW,Cho B,et al.Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia[J].Leukemia,2012,26:2367-2374.
[15]	Kuang P,Liu T,Pan L,et al.Sustaining integrating imatinib and interferon-α into maintenance therapy improves survival of patients with Philadelphia positive acute lymphoblastic leukemia ineligible for allogeneic stem cell transplantation[J].Leuk Lymphoma,2016 Feb 16:1-9.[Epub ahead of print].
[16]	Giebel S,Labopin M,Gorin NC,et al.Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors:a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation[J].Eur J Cancer,2014,50:411-417.
[17]	Brissot E,Labopin M,Beckers MM,et al.Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia[J].Haematologica,2015,100:392-399.
[18]	Soverini S,Vitale A,Poerio A,et al.Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis[J].Haematologica,2011,96:552-557.
[19]	Zabriskie MS,Eide CA,Tantravahi SK,et al.BCR/ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia[J].Cancer Cell,2014,26:428-442.
[20]	Topp MS,Gökbuget N,Zugmaier G,et al.Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL[J].Blood,2012,120:5185-5187.
[21]	Maude SL,Frey N,Shaw PA,et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med,2014,371:1507-1517.